Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
Clinical trial NCT04640142 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04640142
- Sponsor
- Octapharma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-04
- Primary completion
- 2026-09-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.